Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HAE1 (PRO98498)
HAE1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HAE1 (PRO98498) | DRUG | - |
Inclusion Criteria: * Signed Informed Consent Form(s) * Male and females 12-75 years of age with the diagnosis of allergic asthma for 12 months according to the standards of the American Thoracic Society * Baseline FEV1 values ≥ 40% to ≤ 80% of the predicted normal value for the subject * Demonstra...
HAE1 is an investigational small molecule being studied for the treatment of allergic asthma. It was evaluated in patients with moderate to severe allergic asthma, including adolescents aged 12 years and older. HAE1 has not been approved for any indication and remains in clinical development.
HAE1 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating HAE1 in respiratory disease.
HAE1 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program has enrolled 50 participants in total. HAE1 is investigational and has not received FDA approval for any indication.
HAE1 has been studied in one Phase 2 trial, NCT00406965, titled A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma. That trial is completed and enrolled 50 participants. It was an uncontrolled study without randomization or double blinding.
Yes, HAE1 is also known as PRO98498. Both names refer to the same investigational small molecule developed by Roche Holding AG for allergic asthma. Readers searching for PRO98498 will find the same Phase 2 program and the same completed trial, NCT00406965.